Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study.
Rowland T, FitzGerald R, Challenger E, Dickinson L, Else LJ, Walker L, Hale C, Shaw V, Kelly C, Lyon R, Gibney J, Dhamani K, Irwin M, Enever Y, Tetlow M, Wood W, Reynolds H, Chiong J, Osanlou O, Pertinez H, Bullock K, Greenhalf W, Owen A, Lalloo DG, Jacobs M, Hiscox JA, Jaki T, Mozgunov P, Saunders G, Griffiths G, Khoo SH, Fletcher TE; AGILE CST‐6 Study Group.
Rowland T, et al. Among authors: owen a.
Clin Pharmacol Ther. 2026 Jun;119(6):1650-1661. doi: 10.1002/cpt.70261. Epub 2026 Mar 18.
Clin Pharmacol Ther. 2026.
PMID: 41848748
Free PMC article.
Clinical Trial.